サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1632660

免疫療法薬の世界市場：市場規模・シェア・動向分析 (薬剤の種類別・適応症別・地域別)、セグメント別予測 (2025年～2030年)

Immunotherapy Drugs Market Size, Share & Trends Analysis Report By Drug Type (Monoclonal Antibodies, Immunomodulators), By Indication (Infectious Diseases, Cancer), By Region, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 100 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
免疫療法薬の世界市場：市場規模・シェア・動向分析 (薬剤の種類別・適応症別・地域別)、セグメント別予測 (2025年～2030年)
出版日: 2024年12月24日
発行: Grand View Research
ページ情報: 英文 100 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

免疫療法薬市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の免疫療法薬の市場規模は、2030年までに5,772億米ドルに達し、2025年から2030年までのCAGRは13.6%で拡大すると推定されています。

同業界の有利な成長に寄与する主な要因としては、がん、自己免疫疾患、炎症性疾患、感染症などの慢性疾患に対する意識の高まり、医薬品承認に対する政府の支援政策などが挙げられます。慢性疾患治療への標的治療の採用が増加していることから、免疫療法薬への関心が高まり、予測期間中に業界を牽引することが期待されます。

例えば、2022年5月、アストラゼネカと第一三共のエンヘルトゥ (トラスツズマブ) は、HER2陽性乳がんの治療薬として米国で承認を取得しました。その他の標的免疫療法薬としては、カドサイラ (トラスツズマブ・エムタンシン)、テセントリク (アテゾリズマブ) などがあります。2022年6月、F.ホフマン・ラ・ロシュ社はNSCLCの術後補助治療薬としてテセントリクのEU承認を取得しました。加えて、中低所得国のヘルスケアインフラが発展していることと、主要企業による研究開発が活発化していることが、業界の成長に寄与すると予想されます。例えば、2021年12月、ノバルティスAGはオシペルリマブ (BGB-A1217) についてBeiGene, Ltd.と提携し、免疫腫瘍学の研究開発活動を拡大しました。

2021年8月、ファイザー社は円形脱毛症治療薬リトレシチニブの第2b/3相臨床試験の良好な結果を発表しました。さらに、世界のがん罹患率の増加が免疫療法薬の需要を牽引すると予想されています。Globocanの報告によると、2020年には新たに1,930万人のがん患者が診断されると推定されています。さらに、European Society of Medical Oncologyによると、欧州におけるがん罹患率は2020年から2040年の間に21%上昇すると予測されています。このように、がん治療のための様々な免疫療法薬の承認は、業界の成長を増加させると予測されています。

免疫療法薬市場：分析概要

  • モノクローナル抗体セグメントは2024年に76.2%の最大シェアを占めました。この成長は、治療用モノクローナル抗体の研究開発の増加と政府の支援策によるものです。
  • この成長は、心血管疾患、呼吸器疾患、自己免疫疾患などの様々な慢性疾患に対する生物製剤治療の需要が高いことに起因しています。
  • がん分野は、世界のがん罹患率の増加と中低所得国におけるヘルスケアインフラの改善により、2024年の売上高の91.4%を占め、市場を独占しています。
  • 北米の免疫療法市場は2024年の売上高シェア49.9%で世界市場を独占しました。
  • これは、同地域における免疫療法の採用増加、支援的な償還政策、ヘルスケア支出の増加によるものです。

目次

第1章 分析方法・範囲

第2章 エグゼクティブサマリー

第3章 免疫療法薬市場：変動要因・傾向・範囲

  • 市場概要/連関の見通し
  • 市場規模と成長見通し
  • 市場力学
    • 市場促進要因の分析
    • 市場抑制要因の分析
  • 免疫療法薬市場：分析ツール
    • ポーターのファイブフォース分析
    • PESTEL分析

第4章 免疫療法薬市場：薬剤の種類別の推定・動向分析

  • 市場シェア：薬剤の種類別 (2024年・2030年)
  • 薬剤の種類別ダッシュボード
  • 市場規模の予測と動向分析：薬剤の種類別 (2018～2030年)
  • モノクローナル抗体
  • 免疫調節剤
  • ワクチン

第5章 免疫療法薬市場：適応症別の推定・動向分析

  • 市場シェア：適応症別 (2024年・2030年)
  • 適応症別ダッシュボード
  • 市場規模の予測と動向分析：適応症別 (2018～2030年)
  • がん
  • 自己免疫疾患
  • 感染症
  • その他

第6章 免疫療法薬市場：地域別の推定・動向分析

  • 市場シェア：地域別 (2024年・2030年)
  • 市場ダッシュボード：地域別
  • 市場規模の予測と動向分析 (2018～2030年)
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • スウェーデン
    • ノルウェー
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • タイ
    • 韓国
    • オーストラリア
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第7章 競合情勢

  • 参入企業概要
  • 企業の市場ポジション分析
  • 企業分類
  • 戦略マッピング
  • 企業プロファイル/上場企業
    • Amgen Inc.
    • Novartis AG
    • AbbVie Inc.
    • Pfizer Inc.
    • F. Hoffmann-La Roche Ltd
    • Johnson &Johnson Services, Inc.
    • AstraZeneca
    • GSK plc.
    • Sanofi
    • Bayer AG
図表

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global Immunotherapy Drugs Market, by Region, 2018 - 2030 (USD Million)
  • Table 4 Global Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 5 North America Immunotherapy Drugs Market, by Country, 2018 - 2030 (USD Million)
  • Table 6 North America Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 7 U.S. Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 8 Canada Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 9 Mexico Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 10 Europe Immunotherapy Drugs Market, by Country, 2018 - 2030 (USD Million)
  • Table 11 Europe Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 12 Germany Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 13 UK Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 14 France Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 15 Italy Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 16 Spain Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 17 Sweden Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 18 Denmark Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 19 Norway Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 20 Asia Pacific Immunotherapy Drugs Market, by Country, 2018 - 2030 (USD Million)
  • Table 21 Asia Pacific Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 22 China Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 23 Japan Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 24 India Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 25 South Korea Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 26 Australia Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 27 Thailand Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 28 Latin America Immunotherapy Drugs Market, by Country, 2018 - 2030 (USD Million)
  • Table 29 Latin America Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 30 Brazil Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 31 Argentina Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 32 Middle East & Africa Immunotherapy Drugs Market, by Country, 2018 - 2030 (USD Million)
  • Table 33 Middle East & Africa Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 34 South Africa Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 35 Saudi Arabia Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 36 UAE Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 37 Kuwait Immunotherapy Drugs Market, by Drug Type, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Immunotherapy drugs market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Segment outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Immunotherapy drugs market dynamics
  • Fig. 12 Immunotherapy drugs market: Porter's five forces analysis
  • Fig. 13 Immunotherapy drugs market: PESTLE analysis
  • Fig. 14 Immunotherapy drugs market: Drug type segment dashboard
  • Fig. 15 Immunotherapy drugs market: Drug type market share analysis, 2024 & 2030
  • Fig. 16 Monoclonal antibodies market, 2018 - 2030 (USD Million)
  • Fig. 17 Immunomodulator market, 2018 - 2030 (USD Million)
  • Fig. 18 Vaccine market, 2018 - 2030 (USD Million)
  • Fig. 19 Immunotherapy drugs market: Indication segment dashboard
  • Fig. 20 Immunotherapy drugs market: Indication market share analysis, 2024 & 2030
  • Fig. 21 Cancer market, 2018 - 2030 (USD Million)
  • Fig. 22 Autoimmune diseases market, 2018 - 2030 (USD Million)
  • Fig. 23 Infectious diseases market, 2018 - 2030 (USD Million)
  • Fig. 24 Others market, 2018 - 2030 (USD Million)
  • Fig. 25 Immunotherapy drugs market revenue, by region
  • Fig. 26 Regional marketplace: Key takeaways
  • Fig. 27 North America immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 28 U.S. country dynamics
  • Fig. 29 U.S. immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 30 Canada country dynamics
  • Fig. 31 Canada immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 32 Mexico country dynamics
  • Fig. 33 Mexico immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 34 Europe immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 35 UK country dynamics
  • Fig. 36 UK immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 37 Germany country dynamics
  • Fig. 38 Germany immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 39 France country dynamics
  • Fig. 40 France immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 41 Italy country dynamics
  • Fig. 42 Italy immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 43 Spain country dynamics
  • Fig. 44 Spain immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 45 Denmark country dynamics
  • Fig. 46 Denmark immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 47 Sweden country dynamics
  • Fig. 48 Sweden immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 49 Norway country dynamics
  • Fig. 50 Norway immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 51 Asia Pacific immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 52 Japan country dynamics
  • Fig. 53 Japan immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 54 China country dynamics
  • Fig. 55 China immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 56 India country dynamics
  • Fig. 57 India immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 58 Thailand country dynamics
  • Fig. 59 Thailand immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 60 South Korea country dynamics
  • Fig. 61 South Korea immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 62 Australia country dynamics
  • Fig. 63 Australia immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 64 Latin America immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 65 Brazil country dynamics
  • Fig. 66 Brazil immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 67 Argentina country dynamics
  • Fig. 68 Argentina immunotherapy drugs market, 2018 - 2030 (USD Million
  • Fig. 69 MEA immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 70 South Africa country dynamics
  • Fig. 71 South Africa immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 72 Saudi Arabia country dynamics
  • Fig. 73 Saudi Arabia immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 74 UAE country dynamics
  • Fig. 75 UAE immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 76 Kuwait country dynamics
  • Fig. 77 Kuwait immunotherapy drugs market, 2018 - 2030 (USD Million)
  • Fig. 78 Company categorization
  • Fig. 79 Company market position analysis
  • Fig. 80 Strategic framework
目次
Product Code: GVR-4-68039-961-5

Immunotherapy Drugs Market Growth & Trends:

The global immunotherapy drugs market size is estimated to reach USD 577.2 billion by 2030, expanding at a CAGR of 13.6% from 2025 to 2030, according to a new report by Grand View Research, Inc. The key factors contributing to the lucrative growth of the industry include increased awareness about chronic diseases including cancer, autoimmune diseases, inflammatory diseases, and infectious diseases, coupled with supportive government policies for drug approval. The rising adoption of targeted therapies for chronic disease treatment is expected to increase inclination toward immunotherapy drugs, thereby driving the industry during the forecast period.

For instance, in May 2022, AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab) received U.S. approval for treating HER2-positive breast cancer. Other targeted immunotherapy drugs include Kadcyla (trastuzumab emtansine) and Tecentriq (atezolizumab). In June 2022, F. Hoffmann-La Roche Ltd. received EU approval for Tecentriq as an adjuvant treatment for NSCLC. In addition, developing healthcare infrastructure in low- and middle-income countries coupled with increased research & development by key players is anticipated to contribute to the industry growth. For instance, in December 2021, Novartis AG collaborated with BeiGene, Ltd. for ociperlimab (BGB-A1217), therefore expanding its R&D activities in immune-oncology.

In August 2021, Pfizer, Inc. shared positive results from phase 2b/3 clinical trial of ritlecitinib for treating alopecia areata. Moreover, the rise in the incidence of cancer cases worldwide is expected to drive the demand for immunotherapy drugs. As per Globocan reports, an estimated 19.3 million new oncology cases were diagnosed in 2020. Moreover, according to the European Society of Medical Oncology, cancer incidence in Europe is anticipated to rise by 21% between 2020 and 2040. Thus, approvals of various immunotherapy drugs for cancer treatment are predicted to increase industry growth.

Immunotherapy Drugs Market Report Highlights:

  • The monoclonal antibodies segment accounted for the largest share of 76.2% in 2024. This growth is due to increased research and development in therapeutic monoclonal antibodies and supportive government initiatives.
  • The growth can be attributed to the high demand for biologics treatment for various chronic diseases, such as cardiovascular, respiratory, and autoimmune diseases
  • The cancer segment dominated the market, accounting for 91.4% of the revenue in 2024 due to the increased incidence of cancer globally and improved healthcare infrastructure in low- and middle-income countries
  • The North America immunotherapy market dominated the global market, with a revenue share of 49.9% in 2024
  • This is due to the increased adoption of immunotherapy, supportive reimbursement policies, and increased healthcare expenditure in the region

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Immunotherapy Drugs Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Immunotherapy Drugs Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape.
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Immunotherapy Drugs Market: Drug Type Estimates & Trend Analysis

  • 4.1. Drug Type Market Share, 2024 & 2030
  • 4.2. Drug Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Drug Type, 2018 to 2030 (USD Million)
  • 4.4. Monoclonal Antibodies
    • 4.4.1. Monoclonal Antibodies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Immunomodulator
    • 4.5.1. Immunomodulator Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Vaccine
    • 4.6.1. Vaccine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Immunotherapy Drugs Market: Indication Estimates & Trend Analysis

  • 5.1. Indication Market Share, 2024 & 2030
  • 5.2. Indication Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Drug Type, 2018 to 2030 (USD Million)
  • 5.4. Cancer
    • 5.4.1. Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Autoimmune Diseases
    • 5.5.1. Autoimmune Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Infectious Diseases
    • 5.6.1. Infectious Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Others
    • 5.7.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Immunotherapy Drugs Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 6.4. North America
    • 6.4.1. North America Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Regulatory Framework
      • 6.4.2.3. Competitive Insights
      • 6.4.2.4. U.S. Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Regulatory Framework
      • 6.4.3.3. Competitive Insights
      • 6.4.3.4. Canada Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Regulatory Framework
      • 6.4.4.3. Competitive Insights
      • 6.4.4.4. Mexico Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Regulatory Framework
      • 6.5.2.3. Competitive Insights
      • 6.5.2.4. UK Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Regulatory Framework
      • 6.5.3.3. Competitive Insights
      • 6.5.3.4. Germany Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Regulatory Framework
      • 6.5.4.3. Competitive Insights
      • 6.5.4.4. France Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Regulatory Framework
      • 6.5.5.3. Competitive Insights
      • 6.5.5.4. Italy Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Regulatory Framework
      • 6.5.6.3. Competitive Insights
      • 6.5.6.4. Spain Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Regulatory Framework
      • 6.5.7.3. Competitive Insights
      • 6.5.7.4. Denmark Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.8. Sweden
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Regulatory Framework
      • 6.5.8.3. Competitive Insights
      • 6.5.8.4. Sweden Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.9. Norway
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Regulatory Framework
      • 6.5.9.3. Competitive Insights
      • 6.5.9.4. Norway Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Regulatory Framework
      • 6.6.2.3. Competitive Insights
      • 6.6.2.4. Japan Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Regulatory Framework
      • 6.6.3.3. Competitive Insights
      • 6.6.3.4. China Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Regulatory Framework
      • 6.6.4.3. Competitive Insights
      • 6.6.4.4. India Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. Thailand
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Regulatory Framework
      • 6.6.5.3. Competitive Insights
      • 6.6.5.4. Thailand Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.6. South Korea
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Regulatory Framework
      • 6.6.6.3. Competitive Insights
      • 6.6.6.4. South Korea Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.7. Australia
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Regulatory Framework
      • 6.6.7.3. Competitive Insights
      • 6.6.7.4. Australia Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Regulatory Framework
      • 6.7.2.3. Competitive Insights
      • 6.7.2.4. Brazil Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Regulatory Framework
      • 6.7.3.3. Competitive Insights
      • 6.7.3.4. Argentina Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8. Middle East and Africa
    • 6.8.1. Middle East and Africa Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Regulatory Framework
      • 6.8.2.3. Competitive Insights
      • 6.8.2.4. South Africa Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Regulatory Framework
      • 6.8.3.3. Competitive Insights
      • 6.8.3.4. Saudi Arabia Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Regulatory Framework
      • 6.8.4.3. Competitive Insights
      • 6.8.4.4. UAE Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Regulatory Framework
      • 6.8.5.3. Competitive Insights
      • 6.8.5.4. Kuwait Immunotherapy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Amgen Inc.
      • 7.5.1.1. Participant's Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Recent Developments/ Strategic Initiatives
    • 7.5.2. Novartis AG
      • 7.5.2.1. Participant's Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Recent Developments/ Strategic Initiatives
    • 7.5.3. AbbVie Inc.
      • 7.5.3.1. Participant's Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Recent Developments/ Strategic Initiatives
    • 7.5.4. Pfizer Inc.
      • 7.5.4.1. Participant's Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Recent Developments/ Strategic Initiatives
    • 7.5.5. F. Hoffmann-La Roche Ltd
      • 7.5.5.1. Participant's Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Recent Developments/ Strategic Initiatives
    • 7.5.6. Johnson & Johnson Services, Inc.
      • 7.5.6.1. Participant's Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Recent Developments/ Strategic Initiatives
    • 7.5.7. AstraZeneca
      • 7.5.7.1. Participant's Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Recent Developments/ Strategic Initiatives
    • 7.5.8. GSK plc.
      • 7.5.8.1. Participant's Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Product Benchmarking
      • 7.5.8.4. Recent Developments/ Strategic Initiatives
    • 7.5.9. Sanofi
      • 7.5.9.1. Participant's Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Product Benchmarking
      • 7.5.9.4. Recent Developments/ Strategic Initiatives
    • 7.5.10. Bayer AG
      • 7.5.10.1. Participant's Overview
      • 7.5.10.2. Financial Performance
      • 7.5.10.3. Product Benchmarking
      • 7.5.10.4. Recent Developments/ Strategic Initiatives